| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 113.42K | 5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | -0.43% | -0.96% | -1% | - | - | - | - | - | - | - |
| Cost of Goods Sold | 125.88K | 1.38K | 0 | 0 | 0 | 882.06K | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 1.11% | 0.28% | - | - | - | - | - | - | - | - |
| Gross Profit | -12.45K | 3.62K | -1.86K | -630.09K | -877.9K | -882.06K | 0 | 0 | 0 | 0 |
| Gross Margin % | -0.11% | 0.72% | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -1.14% | 1.29% | -1.52% | -336.85% | -0.39% | -0% | 1% | - | - | - |
| Operating Expenses | 974.71K | 1.93M | 1.8M | 4.52M | 3.94M | 14.25M | 12.13M | 27.53M | 11.46M | 12.05M |
| OpEx % of Revenue | 8.59% | 385.3% | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 945.46K | 384.52K | 876.32K | 1.44M | 1.61M | 3.18M | 4.69M | 8.76M | 5.66M | 4.78M |
| SG&A % of Revenue | 8.34% | 76.9% | - | - | - | - | - | - | - | - |
| Research & Development | 29.25K | 6.56K | 926.12K | 3.09M | 2.32M | 11.08M | 6.88M | 11.49M | 5.8M | 7.27M |
| R&D % of Revenue | 0.26% | 1.31% | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 1.85M | 0 | 0 | 0 | 0 | 566.58K | 7.27M | 0 | 0 |
| Operating Income | 2.69M | -1.92M | -1.8M | -4.52M | -3.94M | -15.14M | -12.13M | -27.53M | -11.46M | -12.05M |
| Operating Margin % | 23.73% | -384.3% | - | - | - | - | - | - | - | - |
| Operating Income Growth % | 1.65% | -1.71% | 0.06% | -1.51% | 0.13% | -2.85% | 0.2% | -1.27% | 0.58% | -0.05% |
| EBITDA | 2.93M | -1.92M | -1.8M | -3.89M | -3.06M | -14.25M | -11.34M | -26.74M | -11.46M | -12.05M |
| EBITDA Margin % | 25.83% | -384.03% | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 1.79% | -1.66% | 0.06% | -1.16% | 0.21% | -3.66% | 0.2% | -1.36% | 0.57% | -0.05% |
| D&A (Non-Cash Add-back) | 238.82K | 1.38K | 1.86K | 630.09K | 877.9K | 882.06K | 790.97K | 788.5K | 222 | 782 |
| EBIT | -2.75M | -91.8K | -1.8M | -4.51M | -3.92M | -15.13M | -11.57M | -20.26M | -11.46M | -12.05M |
| Net Interest Income | -230.99K | -245.38K | -30.51K | -142.91K | -25.11K | -277.95K | 11.63K | 101.2K | 335.54K | 201.09K |
| Interest Income | 4.65K | 0 | 5.18K | 18.3K | 11.55K | 3.17K | 11.99K | 101.2K | 335.54K | 201.09K |
| Interest Expense | 235.64K | 245.38K | 35.69K | 161.21K | 36.66K | 281.12K | 362 | 0 | 0 | 0 |
| Other Income/Expense | -5.67M | 4.45K | -53.88K | -142.91K | -25.11K | -277.95K | 175.4K | 101.2K | 335.54K | 201.09K |
| Pretax Income | -2.98M | -337.18K | -1.86M | -4.67M | -3.96M | -15.41M | -11.96M | -27.42M | -11.12M | -11.85M |
| Pretax Margin % | -26.3% | -67.44% | - | - | - | - | - | - | - | - |
| Income Tax | 100 | -1.2K | -18.19K | -902.8K | -602.72K | -1M | -530.61K | 0 | 0 | 0 |
| Effective Tax Rate % | 1.12% | 1% | 1% | 0.81% | 0.85% | 1.24% | 0.96% | 1% | 1% | 1% |
| Net Income | -3.35M | -335.98K | -1.86M | -3.77M | -3.36M | -19.04M | -11.43M | -27.42M | -11.12M | -11.85M |
| Net Margin % | -29.57% | -67.2% | - | - | - | - | - | - | - | - |
| Net Income Growth % | 0.26% | 0.9% | -4.53% | -1.03% | 0.11% | -4.67% | 0.4% | -1.4% | 0.59% | -0.07% |
| Net Income (Continuing) | -2.98M | -337.18K | -1.86M | -3.77M | -3.36M | -14.41M | -11.43M | -27.42M | -11.12M | -11.85M |
| Discontinued Operations | -371.31K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -298.40 | -29.89 | -8.00 | -14.20 | -12.17 | -50.77 | -14.92 | -1.70 | -8.48 | -3.87 |
| EPS Growth % | 0.55% | 0.9% | 0.73% | -0.78% | 0.14% | -3.17% | 0.71% | 0.89% | -3.99% | 0.54% |
| EPS (Basic) | -298.40 | -29.89 | -8.00 | -14.20 | -12.17 | -50.77 | -14.92 | -1.70 | -8.48 | -3.87 |
| Diluted Shares Outstanding | 11.24K | 11.24K | 232.83K | 266.61K | 275.87K | 374.98K | 765.97K | 16.11M | 1.31M | 3.06M |
| Basic Shares Outstanding | 11.24K | 11.24K | 232.83K | 266.61K | 275.87K | 374.98K | 765.97K | 16.11M | 1.31M | 3.06M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 104.16K | 3.24K | 2.95M | 2.02M | 1.01M | 16.2M | 18.33M | 8.39M | 5.63M | 1.87M |
| Cash & Short-Term Investments | 2.09K | 3.24K | 2.85M | 1.74M | 691.54K | 15.42M | 16.5M | 6.5M | 4.71M | 1.19M |
| Cash Only | 2.09K | 3.24K | 2.85M | 1.74M | 691.54K | 15.42M | 16.5M | 6.5M | 4.71M | 1.19M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 62.71K | 21.58K | 0 | 231.75K | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 54.35K | 0 | 0 | 0 | 0 | 0 | 70.27K | 0 | 926.3K | 0 |
| Total Non-Current Assets | 159 | 27.93K | 31.36K | 10.46M | 9.88M | 9.01M | 8.14M | 233.12K | 154.15K | 1.36M |
| Property, Plant & Equipment | 159 | 22.39K | 25.82K | 17.38K | 228K | 159.04K | 74.18K | 227.59K | 148.61K | 75.69K |
| Fixed Asset Turnover | 713.36x | 0.22x | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 10.44M | 9.64M | 8.85M | 8.06M | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 1.8M | -1.12M | -1.9M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 5.53K | 5.54K | -2.53M | 5.54K | 5.54K | 5.54K | 5.54K | 5.54K | 1.28M |
| Total Assets | 104.32K | 3.24K | 2.98M | 13.21M | 10.88M | 25.21M | 26.46M | 8.62M | 5.79M | 3.23M |
| Asset Turnover | 1.09x | 1.54x | - | - | - | - | - | - | - | - |
| Asset Growth % | -0.96% | -0.97% | 920.51% | 3.43% | -0.18% | 1.32% | 0.05% | -0.67% | -0.33% | -0.44% |
| Total Current Liabilities | 2.08M | 97.69K | 2.6M | 645.7K | 1.19M | 1.22M | 971.02K | 998.56K | 730.58K | 1.53M |
| Accounts Payable | 159.25K | 166.16K | 50.69K | 292.1K | 75.61K | 320.69K | 218.91K | 327.55K | 311.62K | 880.88K |
| Days Payables Outstanding | 461.77 | 43.92K | - | - | - | 132.7 | - | - | - | - |
| Short-Term Debt | 1.37M | 1.61M | 2.45M | 230K | 802.5K | 117.57K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 483.91K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 557.28K | 0 | 436 | 0 | 316 | 469.86K | 401.77K | 189.05K | 189.04K | 0 |
| Current Ratio | 0.05x | 0.03x | 1.14x | 3.13x | 0.85x | 13.27x | 18.87x | 8.40x | 7.71x | 1.22x |
| Quick Ratio | 0.05x | 0.03x | 1.14x | 3.13x | 0.85x | 13.27x | 18.87x | 8.40x | 7.71x | 1.22x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 9.96K | 2.13M | 1.68M | 1.05M | 7.38K | 150.55K | 66.91K | 487 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 44.88K | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 147.39K | 78.46K | 7.38K | 150.55K | 66.91K | 487 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.53M | 530.61K | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 9.96K | 2.13M | 0 | 400K | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.08M | 2.35M | 2.61M | 3.51M | 2.87M | 2.27M | 978.4K | 1.15M | 797.48K | 1.53M |
| Total Debt | 1.37M | 1.61M | 2.45M | 230K | 1.03M | 328.12K | 78.46K | 229.45K | 150.55K | 73.51K |
| Net Debt | 1.36M | 1.61M | -398.86K | -1.51M | 336.35K | -15.09M | -16.42M | -6.27M | -4.56M | -1.12M |
| Debt / Equity | - | - | 6.56x | 0.02x | 0.13x | 0.01x | 0.00x | 0.03x | 0.03x | 0.04x |
| Debt / EBITDA | 0.47x | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.47x | - | - | - | - | - | - | - | - | - |
| Interest Coverage | 11.42x | -7.83x | -50.50x | -28.07x | -107.36x | -53.84x | -33518.07x | - | - | - |
| Total Equity | -1.98M | -2.35M | 373.16K | 9.7M | 8.01M | 22.94M | 25.49M | 7.47M | 4.99M | 1.7M |
| Equity Growth % | -2.64% | -0.19% | 1.16% | 25% | -0.17% | 1.86% | 0.11% | -0.71% | -0.33% | -0.66% |
| Book Value per Share | -176.10 | -209.14 | 1.60 | 36.39 | 29.04 | 61.17 | 33.27 | 0.46 | 3.80 | 0.55 |
| Total Shareholders' Equity | -1.98M | -2.35M | 373.16K | 9.7M | 8.01M | 22.94M | 25.49M | 7.47M | 4.99M | 1.7M |
| Common Stock | 1.1K | 1.1K | 3.53K | 3.87K | 549 | 1.42K | 1.57K | 1.61K | 129 | 371 |
| Retained Earnings | -14.87M | -15.25M | -3.86M | -7.62M | -10.98M | -25.4M | -36.82M | -64.25M | -75.37M | -87.22M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -300K | -300K | -300K |
| Accumulated OCI | -18.99K | -19.15K | -3.25K | -1.8M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -871.91K | -43.2K | -1.65M | -3.71M | -2.75M | -3.14M | -8.72M | -9.61M | -8.06M | -11.25M |
| Operating CF Margin % | -7.69% | -8.64% | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 0.68% | 0.95% | -37.3% | -1.24% | 0.26% | -0.14% | -1.77% | -0.1% | 0.16% | -0.39% |
| Net Income | -2.98M | -337.18K | -1.86M | -3.77M | -3.36M | -14.41M | -11.43M | -27.42M | -11.12M | -11.85M |
| Depreciation & Amortization | 238.82K | 159 | 1.86K | 630.09K | 803.77K | 803.77K | 790.97K | 788.5K | 222 | 782 |
| Stock-Based Compensation | 96.93K | 6.69K | 0 | 74.06K | 510.48K | 2.73M | 3.41M | 8.83M | 1.06M | 629.51K |
| Deferred Taxes | 1.54M | 7.92K | 0 | -902.8K | -602.72K | -1M | -530.61K | 0 | 0 | 0 |
| Other Non-Cash Items | 83.3K | 967 | 38.7K | 67.07K | 75.91K | 8.88M | 220.61K | 7.66M | 1.39M | 87.18K |
| Working Capital Changes | 153.5K | 278.24K | 161.13K | 188.71K | -179.71K | -140.39K | -1.18M | 543.6K | 605.21K | -112.4K |
| Change in Receivables | 213.41K | 0 | 0 | 0 | 0 | -77.02K | 6.75K | 70.27K | 0 | 0 |
| Change in Inventory | -7.07K | 0 | 0 | 0 | 0 | 77.02K | -6.75K | 0 | 0 | 0 |
| Change in Payables | 5.32K | -10.34K | 0 | 241.42K | -216.49K | 245.08K | -101.79K | 108.64K | -15.93K | 569.26K |
| Cash from Investing | 40.2K | 17K | 1M | -22.28K | 0 | 0 | 0 | 0 | -2.78K | -3.24K |
| Capital Expenditures | -1.4K | -23.77K | -20.62K | -22.28K | 0 | 0 | 0 | 0 | -2.78K | -3.24K |
| CapEx % of Revenue | 0.01% | 4.75% | - | - | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 41.6K | 40.77K | 1.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 821.1K | 15K | 2.43M | 2.62M | 1.7M | 17.87M | 9.8M | -388.84K | 6.27M | 7.73M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 0 | -154.8K | -250.96K | 895.72K | 0 | -186.49K | -88.84K | -52.75K | -8.56K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -873.3K | -66.98K | -1.68M | -3.73M | -2.75M | -3.14M | -8.72M | -9.61M | -8.07M | -11.25M |
| FCF Margin % | -7.7% | -13.4% | - | - | - | - | - | - | - | - |
| FCF Growth % | 0.68% | 0.92% | -24.01% | -1.23% | 0.26% | -0.14% | -1.77% | -0.1% | 0.16% | -0.39% |
| FCF per Share | -77.72 | -5.96 | -7.20 | -13.98 | -9.97 | -8.38 | -11.38 | -0.60 | -6.15 | -3.68 |
| FCF Conversion (FCF/Net Income) | 0.26x | 0.13x | 0.89x | 0.98x | 0.82x | 0.17x | 0.76x | 0.35x | 0.73x | 0.95x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -497.45% | -74.75% | -37.91% | -123.03% | -47.2% | -166.43% | -178.52% | -354.51% |
| Return on Invested Capital (ROIC) | 263.36% | - | - | -83.13% | -35.69% | -140.15% | -107.58% | -402.32% | -1054.26% | -1786.48% |
| Gross Margin | -10.98% | 72.38% | - | - | - | - | - | - | - | - |
| Net Margin | -2957.22% | -6719.64% | - | - | - | - | - | - | - | - |
| Debt / Equity | - | - | 6.56x | 0.02x | 0.13x | 0.01x | 0.00x | 0.03x | 0.03x | 0.04x |
| Interest Coverage | 11.42x | -7.83x | -50.50x | -28.07x | -107.36x | -53.84x | -33518.07x | - | - | - |
| FCF Conversion | 0.26x | 0.13x | 0.89x | 0.98x | 0.82x | 0.17x | 0.76x | 0.35x | 0.73x | 0.95x |
| Revenue Growth | -43.34% | -95.59% | -100% | - | - | - | - | - | - | - |
Processa Pharmaceuticals, Inc. (PCSA) grew revenue by 0.0% over the past year. Growth has been modest.
Processa Pharmaceuticals, Inc. (PCSA) reported a net loss of $12.9M for fiscal year 2024.
Processa Pharmaceuticals, Inc. (PCSA) has a return on equity (ROE) of -354.5%. Negative ROE indicates the company is unprofitable.
Processa Pharmaceuticals, Inc. (PCSA) had negative free cash flow of $10.7M in fiscal year 2024, likely due to heavy capital investments.